S Lakshmanan
Source : Pharmabiz.com
The face of Indian regulatory affairs is changing. The government of India is taking enormous steps to showcase India as the destination for multinational companies to conduct their global clinical trials in India. Pharma companies and CROs are keen looking on India since the development cost of a new drug is comparatively one -fifth of other developed countries.The vibrant nature of Indian regulatory affairs is gaining rapidly the attention of world countries since India is turning to be the credible destination. As Indian regulatory affairs increase in complexity and scope, and globalization occurs within the field, there will be constant watch from the developed countries
No comments:
Post a Comment